Get the latest news, insights, and market updates on RIGL (Rigel Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Rigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries. Feb 3, 2026 - $RIGL
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow
Rigel Pharmaceuticals just saw its fair value estimate nudged from US$51.20 to US$51.60, a small move that still reflects some meaningful shifts in the story behind the stock. The model now blends more cautious assumptions around revenue growth with updated 2025 net product sales guidance of US$225m to US$230m and the support of positive cash flow, tying the new target closely to how current execution stacks up against earlier expectations. Stay with this article to see how you can keep track... Jan 20, 2026 - $RIGL
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative?
Rigel Pharmaceuticals recently issued full-year 2026 guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenues. This guidance, paired with earlier strong product and contract revenue performance, highlights how Rigel is leaning on its commercial portfolio to underpin near-term growth expectations. We will now examine how Rigel’s newly issued 2026 revenue... Jan 16, 2026 - $RIGL
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the Best Performing Affordable Stocks Under $40. On January 12, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its preliminary results for the fourth quarter of 2025 and also provided its 2026 outlook. Although the company is set to release its official results on March 3, the preliminary data suggests that […] Jan 16, 2026 - $RIGL
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance
Rigel Pharmaceuticals (RIGL) recently issued full year 2026 guidance, indicating anticipated total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue. See our latest analysis for Rigel Pharmaceuticals. The new 2026 guidance lands after a sharp 1 year total shareholder return of 127.44% and a 90 day share price return of 35.04%. However, recent 7 day and 30 day share price... Jan 14, 2026 - $RIGL
Rigel Provides Business Update and 2026 Outlook
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2025, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2026. Jan 12, 2026 - $RIGL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple